Kalin Ron, Stanton Marshall S
Cardiac Rhythm Management Division, Medtronic Inc., MS:T135, 7000 Central Avenue NE, Minneapolis, MN 55432, USA.
Pacing Clin Electrophysiol. 2005 Apr;28(4):326-8. doi: 10.1111/j.1540-8159.2005.50024.x.
Dramatic increases in both magnetic resonance imaging (MRI) usage and cardiac device-based therapy have resulted in an estimated 50-75% probability of a patient being indicated for an MRI over the lifetime of their device. Some recent studies have demonstrated "safe procedures" and "no adverse events" in the limited populations, clinical situations, and specific devices and lead orientations tested. While these investigations are useful to help ascertain the hazards for patients with cardiac devices, they do not demonstrate clear freedom from risk. All components of active implantable systems must be engineered during the design stage to provide safety in current and evolving MR environments. Device manufacturers need to secure regulatory approval to confirm their products' safety under multiple clinical and technical variables.
磁共振成像(MRI)使用量和基于心脏设备的治疗方法都急剧增加,据估计,在患者使用设备的整个生命周期内,有50%至75%的概率会被建议进行MRI检查。最近的一些研究在有限的人群、临床情况以及特定的设备和导线方向测试中证明了“安全程序”和“无不良事件”。虽然这些调查有助于确定心脏设备患者面临的风险,但它们并未表明完全没有风险。有源植入系统的所有组件在设计阶段都必须进行工程设计,以在当前和不断发展的MR环境中提供安全性。设备制造商需要获得监管批准,以确认其产品在多种临床和技术变量下的安全性。